Penumbra Inc (PEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Penumbra Inc (PEN) has a cash flow conversion efficiency ratio of 0.059x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($86.97 Million) by net assets ($1.47 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PEN net asset quality index to measure how much of total assets are equity-financed.
Penumbra Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Penumbra Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Penumbra Inc (PEN) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Penumbra Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Penumbra Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Equity Lifestyle Properties Inc
NYSE:ELS
|
0.107x |
|
TransUnion
NYSE:TRU
|
0.017x |
|
Canara Bank
NSE:CANBK
|
-1.285x |
|
Ascendis Pharma AS
F:A71
|
-0.016x |
|
Allegro.eu S.A.
WAR:ALE
|
0.012x |
|
Ally Financial Inc
NYSE:ALLY
|
0.078x |
|
GAIL (India) Limited
NSE:GAIL
|
0.065x |
|
Aditya Birla Capital Limited
NSE:ABCAPITAL
|
-0.407x |
Annual Cash Flow Conversion Efficiency for Penumbra Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Penumbra Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Penumbra Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.43 Billion | $238.66 Million | 0.167x | +14.20% |
| 2024-12-31 | $1.15 Billion | $168.48 Million | 0.146x | +77.31% |
| 2023-12-31 | $1.18 Billion | $97.33 Million | 0.083x | +248.16% |
| 2022-12-31 | $998.86 Million | $-55.66 Million | -0.056x | -659.43% |
| 2021-12-31 | $953.93 Million | $9.50 Million | 0.010x | +119.11% |
| 2020-12-31 | $637.79 Million | $-33.24 Million | -0.052x | -194.97% |
| 2019-12-31 | $485.61 Million | $26.65 Million | 0.055x | -19.52% |
| 2018-12-31 | $422.42 Million | $28.81 Million | 0.068x | +115.17% |
| 2017-12-31 | $400.41 Million | $12.69 Million | 0.032x | +165.97% |
| 2016-12-31 | $266.55 Million | $-12.81 Million | -0.048x | +49.85% |
| 2015-12-31 | $232.52 Million | $-22.28 Million | -0.096x | -118.55% |
| 2014-12-31 | $-12.37 Million | $-6.39 Million | 0.516x | +22.61% |
| 2013-12-31 | $-8.06 Million | $-3.40 Million | 0.421x | -- |
About Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombecto… Read more